sfondo pallini

EryDel to present at
Italian A-T Association Family Weekend

close button

September 18, 2019

Download pdf logo twitter logo linkedin

Bresso (MI), Italy – 18 September 2019 - EryDel SpA (www.erydel.com), a biotech company specializing in the development and commercialization of drugs and diagnostics delivered through autologous red blood cells, today announced that Alyssa Wyant, Senior Vice President, Regulatory Affairs, will represent EryDel at the ANAT (Associazione Nazionale Atassia Telangiectasia) Family Weekend on 20-22 September, 2019, in Monterenzio, Bologna. The ANAT Family Weekend is planned to occur prior to World Ataxia Day, which is celebrated worldwide on 25 September. The Company will present an update on the Phase III study, ATTeST (www.attest-trial.com), at 10:00 a.m. on 21 September.

About EryDel

EryDel SpA is a biotechnology company specializing in the development of drugs delivered through red blood cells (RBCs) by using a proprietary medical device technology. Its most advanced product, EryDex System (EDS) is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC’s delivery technology for the treatment of other rare diseases.

About Ataxia Telangiectasia

Ataxia Telangiectasia (AT) is a rare genetic disease caused by biallelic mutations in the ataxia telangiectasia mutated (ATM) gene, for which no established therapy is currently available. ATM encodes a PI3Kinase protein shown to play a pivotal role in response to DNA damage and cell cycle control. Homozygosity for ATM mutations result in a multi-systemic disorder, involving mainly the nervous and immune systems. The major clinical feature of AT is severe progressive neurodegeneration from early infancy. Specific features include progressive ataxia of the trunk and limbs, involuntary movements, oculomotor apraxia, difficulties with speech and swallowing, and delayed peripheral neuropathy. Other clinical features of patients with the classical phenotype include oculocutaneous telangiectasia, immunodeficiency with recurrent respiratory tract infections, radio sensitivity and an increased incidence of cancer.

Media contact: Emanuela Germi at +39 02 36504470 or emanuela.germi@erydel.com